VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis
Oral, once-daily doses of VYN202 being evaluated in subjects with moderate-to-severe plaque psoriasisTop-line data from the 12-week double-blind ...
VYNE Therapeutics announces dosing of first patient in Phase 1b trial of VYN202
VYNE Therapeutics (VYNE) announced that the first subject has been dosed in a Phase 1b trial evaluating VYN202 in moderate-to-severe plaque ...
Nasdaq5d
VYNE Therapeutics Initiates Phase 1b Trial Of VYN202 For Plaque Psoriasis Treatment
(RTTNews) - VYNE Therapeutics Inc. (VYNE) announced the initiation of a Phase 1b trial evaluating VYN202, a BD2-selective BET inhibitor, for the treatment of moderate-to-severe plaque psoriasis ...
di1mon
Fyr är Årets Affärskrog 2024 – Vyn är Årets Resmål
Restaurang Fyr i Halmstad är vinnare av Di Weekends restaurangpris Årets Affärskrog 2024. Daniel Berlins lyxkrog Vyn belönas med utmärkelsen Årets Resmål. Samtidigt tilldelas Ulf Johansson på 28+ i ...